-
Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial. J. Urol. (IF 5.9) Pub Date : 2024-12-18 Ekene A Enemchukwu,Susan Kalota,Kaiser Robertson,Sijian Ge,Jingmei Lu,Hanh Badger,Salim Mujais,Kenneth M Peters
PURPOSE To assess efficacy and safety of URO-902, an investigational gene therapy expressing the α subunit of the large-conductance Ca2+-activated K+ channel, in a phase 2a placebo-controlled trial in women with overactive bladder (OAB). MATERIALS AND METHODS Women, 40‒79 years, with OAB and urge urinary incontinence (UUI) who were refractory to OAB medications were randomized to single-dose URO-902
-
Stimulated Raman Histology and Artificial Intelligence Provide Near Real-Time Interpretation of Radical Prostatectomy Surgical Margins. J. Urol. (IF 5.9) Pub Date : 2024-12-17 Miles P Mannas,Fang-Ming Deng,Adrian Ion-Margineanu,Christian Freudiger,Lea Lough,William Huang,James Wysock,Richard Huang,Steve Pastore,Derek Jones,Deepthi Hoskoppal,Jonathan Melamed,Daniel A Orringer,Samir S Taneja
INTRODUCTION Balancing surgical margins and functional outcomes is crucial during radical prostatectomy for prostate cancer. Stimulated Raman Histology (SRH) is a novel, real-time imaging technique that provides histologic images of fresh, unprocessed, and unstained tissue within minutes, which can be interpreted by either humans or artificial intelligence. METHODS Twenty-two participants underwent
-
Long-Term Decision Regret and Associated Factors Following Urinary Reconstruction in Underserved Patients with Spinal Cord Injury. J. Urol. (IF 5.9) Pub Date : 2024-12-17 Aidin Abedi,Luis Morales Ojeda,Stefania Montero,Nhi Ha,Priya Kohli,Petr Gaburak,Armita Abedi,David Chapman,Evgeniy Kreydin,David A Ginsberg
PURPOSE Patients with refractory neurogenic bladder dysfunction may require urinary reconstruction due to severe incontinence, difficulty with catheterization, and to prevent upper urinary tract compromise. We evaluated long-term decisional regret and associated factors following urinary reconstruction in spinal cord injury patients. MATERIALS AND METHODS We interviewed patients with spinal cord injuries
-
Perioperative Complications and Omission of Ureteral Stents During Robot-Assisted Radical Cystectomy with Intracorporeal Ileal Conduit. J. Urol. (IF 5.9) Pub Date : 2024-12-12 Jacob E Tallman,Emily A Vertosick,Syed M Alam,Fady J Baky,S Machele Donat,Eugene J Pietzak,Eugene K Cha,Timothy F Donahue,Bernard H Bochner,Andrew J Vickers,Alvin C Goh
PURPOSE Ureteral stents are commonly placed intraoperatively during radical cystectomy, though their efficacy in reducing complications is unproven. We compared clinical outcomes among patients undergoing robot-assisted radical cystectomy with intracorporeal ileal conduit (RARC-IC) with or without ureteral stents to determine if omission of ureteral stents affects postoperative complications. MATERIALS
-
The Upper TRACT Endometry Score: development and internal validation of an objective measure of variables that impact endoscopic procedures for upper tract urothelial carcinoma. J. Urol. (IF 5.9) Pub Date : 2024-12-12 Suzanne Lange,Alec Reinhardt,Daniel Igel,Craig Labbate,Mehrad Adibi,Suprateek Kundu,Surena Matin
PURPOSE Endoscopic management (EM) is an increasingly accepted option for upper tract urothelial carcinoma (UTUC). Feasibility can be dependent on a variety of variables. The objective of this study was to identify anatomic and phenotypic tumor characteristics that impact EM, using structured expert forecasting, develop and obtain consensus on an assessment score, and perform initial validation of
-
Long-term Urinary and Sexual Outcomes in Pediatric Genitourinary Rhabdomyosarcoma Survivors: A Qualitative Study. J. Urol. (IF 5.9) Pub Date : 2024-12-12 Rachel A Saunders,Andrea K Balthazar,Christopher D Jaeger,Monah Javidan-Nejad,Candace Y Chung,Judith A Vessey,Richard S Lee,Hsin-Hsiao Scott Wang
PURPOSE Genitourinary rhabdomyosarcoma (GU-RMS) often requires multimodal therapy treatment including radiation, chemotherapy, and radical surgery for disease control. The long-term effects of the disease and associated treatments are unclear. We sought to investigate the long-term genitourinary quality of life for adult survivors of pediatric GU-RMS. MATERIALS AND METHODS In total, 14 subjects (43%
-
Impact of Discordance Between MRI and US Volume Measurements on Prostate Fusion Biopsy Outcomes. J. Urol. (IF 5.9) Pub Date : 2024-12-10 Tabea Borde,Nicole A Varble,Lindsey A Hazen,Laetitia Saccenti,Charisse Garcia,Meredith Digennaro,Sandeep Gurram,Peter A Pinto,Baris Turkbey,Bradford J Wood
PURPOSE To determine whether the difference between MRI-based and ultrasound (US)-based volume measurements are associated with MRI/US-targeted fusion-guided biopsy outcomes. MATERIALS AND METHODS This retrospective, single-center study involved 4177 consecutive patients biopsied between 2010 and 2023 using both MRI/US-targeted fusion and systematic biopsy. Biopsies were indicated because of elevated
-
The Journal of Urology® Home Study Course 2025 Volume 213/214. J. Urol. (IF 5.9) Pub Date : 2024-12-10
-
Artificial Intelligence as a Discriminator of Competence in Urological Training: Are we there? J. Urol. (IF 5.9) Pub Date : 2024-12-09 Naji J Touma,Ruchit Patel,Thomas Skinner,Michael Leveridge
INTRODUCTION Assessments in medical education play a central role in evaluating trainees' progress and eventual competence. Generative artificial intelligence (AI) is finding an increasing role in clinical care and medical education. The objective of this study is to evaluate the ability of the large language model ChatGPT to generate exam questions that are discriminating in the evaluation of graduating
-
Development of Prediction Models for Severe Pain and Urinary Symptoms after Ureteroscopy with Ureteral Stent Placement: Results from the STENTS Study and Initial Validation of Pain Interference. J. Urol. (IF 5.9) Pub Date : 2024-12-09 Gregory E Tasian,Jonathan D Harper,Hussein R Al-Khalidi,Hongqiu Yang,Naim M Maalouf,Michele Curatolo,H Henry Lai,Alana Desai,Jodi A Antonelli,Jing Huang,Justin B Ziemba,Hunter Wessells,Ziya Kirkali,Charles D Scales,Peter P Reese
PURPOSE We developed prediction models for severe pain and urinary symptoms after ureteroscopy with ureteral stent placement. MATERIALS AND METHODS The development cohort included 424 adults and adolescents enrolled in the multicenter STENTS prospective cohort study who underwent ureteroscopy with stent placement for urinary stones. The validation cohort was an independent prospective cohort of 115
-
Development and Validation of the Length, Segment, and Etiology (LSE) Anterior Urethral Stricture Disease Staging System Using Longitudinal Urethroplasty Outcomes Data from the Trauma and Urologic Reconstruction Network of Surgeons. J. Urol. (IF 5.9) Pub Date : 2024-12-09 Bradley A Erickson,Mei N Tuong,Alithea N Zorn,Charles H Schlaepfer,Nejd F Alsikafi,Benjamin N Breyer,Joshua A Broghammer,Jill C Buckley,Sean P Elliott,Jeremy B Myers,Andrew C Peterson,Keith F Rourke,Thomas G Smith,Alex J Vanni,Bryan B Voelzke,Lee C Zhao
PURPOSE To create and validate an anterior urethral stricture disease (aUSD) staging system based on the previously validated Length (L), Urethral Segment (S), and Etiology (E, LSE) classification system. MATERIALS/METHODS The Trauma and Urologic Reconstruction Network of Surgeons (TURNS) prospective database was used to create and validate the staging system. A novel Urethroplasty Triad Score (UTS)
-
Diagnostic Test Characteristics of Ultrasound-Based Hydronephrosis for Chronic Kidney Disease in Children and Adolescents With Myelomeningocele: Results From the UMPIRE and NSBPR Cohort Studies. J. Urol. (IF 5.9) Pub Date : 2024-12-09 David I Chu,Tiebin Liu,Tonya Williams,Jacqueline Mix,Jennifer Ahn,J Christopher Austin,Michelle Baum,Douglass Clayton,Susan Jarosz,David Joseph,Elizabeth Roth,Jonathan Routh,Duong Tu,Evalynn Vasquez,M Chad Wallis,John Wiener,Earl Cheng,Elizabeth Yerkes,Stacy Tanaka
PURPOSE Renal ultrasounds are performed in patients with myelomeningocele to screen for markers of kidney health, including hydronephrosis. We evaluated the diagnostic accuracy of hydronephrosis to screen for low kidney function defined by estimated glomerular filtration rate (eGFR). MATERIALS AND METHODS We performed a retrospective cross-sectional study using data from 2 cohorts of children and youth
-
Prevalence, incidence, and age at diagnosis of males with hypospadias - a nationwide population-based epidemiological study. J. Urol. (IF 5.9) Pub Date : 2024-12-03 Tina L Leunbach,Agnethe Berglund,Andreas Ernst,Gitte M Hvistendahl,Yazan F Rawashdeh,Claus H Gravholt
PURPOSE To assess the diagnostic prevalence, incidence, diagnostic age, and surgical volume of hypospadias in Denmark. MATERIALS AND METHODS Males with a hypospadias diagnosis in the Danish National Patient Registry (n=10,276) were identified (1977-2019). A diagnostic algorithm, validated via medical file review (n=1,710), confirmed diagnoses and severity (distal/proximal). The yearly prevalence (live-born
-
Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality. J. Urol. (IF 5.9) Pub Date : 2024-12-02 Anita Robert,Ranjeeta Mallick,Daniel I McIsaac,Luke T Lavallée,Bimal Bhindi,Daniel Heng,Lori A Wood,Ricardo Rendon,Simon Tanguay,Anthony Finelli,Rahul K Bansal,Aly-Khan Lalani,Naveen Basappa,Miles P Mannas,Jasmir G Nayak,Georg A Bjarnason,Jean-Baptiste Lattouf,Frédéric Pouliot,Patrick O Richard,Camilla Tajzler,Rodney H Breau
PURPOSE Postoperative prognostic tools allow for improved prediction of future recurrence risk, patient counseling, and assessment of eligibility for adjuvant treatments and ensure appropriate follow-up surveillance. The purpose of this analysis was to validate existing prognostic models for patients with kidney cancer. MATERIALS AND METHODS The Canadian Kidney Cancer information system is a prospective
-
Spontaneous resolution of primary obstructive megaureter: Risk stratification and prediction based on early sonographic factors. J. Urol. (IF 5.9) Pub Date : 2024-12-02 Adree Khondker,Jin Kyu Kim,Ihtisham Ahmad,Jethro Cc Kwong,Kay Rivera,Camilla B Moreno,Michael E Chua,Mandy Rickard,Armando J Lorenzo
PURPOSE To describe and develop predictors for spontaneous resolution of primary obstructive megaureter (POM) from early ultrasound measures. METHODS Children referred to our institution between 2007 and 2023 for POM were reviewed. POM was defined as hydroureteronephrosis with ureteral dilatation >7mm. We excluded patients with other etiologies for upper tract dilatation. Resolution was defined as
-
Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes. J. Urol. (IF 5.9) Pub Date : 2024-12-02 Mohamed E Ahmed,Jack R Andrews,Ahmed M Mahmoud,Giuseppe Reitano,Prabin Thapa,Mark D Tyson,Abhinav Khanna,Paras Shah,Vidit Sharma,R Houston Thompson,Stephen A Boorjian,Igor Frank,Matthew K Tollefson,R Jeffrey Karnes
BACKGROUND Perioperative blood transfusion has been reported in > 50% of patients undergoing Radical cystectomy (RC). Unfortunately, perioperative blood transfusion in patients undergoing RC has been associated with poor oncological outcomes. Tranexamic acid (TXA) use has been proposed to decrease the need for perioperative blood transfusion. Here, we seek to investigate the impact of intraoperative
-
Two-year efficacy and safety outcomes of the pivotal OASIS Study using the Revi® System for treatment of urgency urinary incontinence. J. Urol. (IF 5.9) Pub Date : 2024-11-25 John P F A Heesakkers,Philip Toozs-Hobson,Suzette E Sutherland,Alex Digesu,Cindy L Amundsen,Rebecca J McCrery,Stefan De Wachter,Emily R Kean,Frank Martens,Kevin Benson,Kimberly L Ferrante,Kevin J Cline,Osvaldo F Padron,Laura Giusto,Felicia L Lane,Lambertus P W Witte,Roger R Dmochowski
PURPOSE The BlueWind Medical Device, Revi®, is a novel implantable tibial neuromodulation system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence (i.e., overactive bladder wet). The Revi System is the first FDA-cleared implantable neuromodulation device which can be used without prior failure with
-
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. J. Urol. (IF 5.9) Pub Date : 2024-12-02 Phillip M Pierorazio,Nir Kleinmann,Ahmad Shabsigh,Brian Hu,Jay D Raman,Hristos Kaimakliotis,Alexander Sankin,Nirmish Singla,Andrew Meads,Brent Burger,Sunil Raju,Michael J Louie,Karim Chamie,Alon Weizer,Mark Schoenberg
PURPOSE To evaluate long-term outcomes of primary chemoablation using a mitomycin reverse thermal gel (UGN-101) in patients with low-grade upper tract urothelial carcinoma. MATERIALS AND METHODS Patients who participated in the OLYMPUS trial (TC-UT-03, NCT02793128) and achieved a complete response (CR) after 6-weekly doses of UGN-101 were followed up to 12 months after initial CR. Those with CR at
-
Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer. J. Urol. (IF 5.9) Pub Date : 2024-11-19 Pedro Ramos,João P Brás,Carolina Dias,Mafalda Bessa-Gonçalves,Francisco Botelho,João Silva,Carlos Silva,Luís Pacheco-Figueiredo
PURPOSE Alternative, noninvasive, cost-effective methods to complement or serve as substitutes to current standard-of-care (SOC) procedures in NMIBC follow-up are needed. Uromonitor is a urine biomarker test detecting bladder cancer recurrence through the screening of TERT, FGFR3, and KRAS hotspot mutations. The aim of this study was to assess Uromonitor performance by comparing it with the current
-
What is the Standard of Care For Multifocal Low-Grade Bladder Cancer? J. Urol. (IF 5.9) Pub Date : 2024-11-18 Eugene Pietzak,Christopher B Anderson
-
High 11-Ketotestosterone Linked to Shorter Time to Castration Resistance in Recurrent Nonmetastatic Prostate Cancer. J. Urol. (IF 5.9) Pub Date : 2024-11-15 Cylia Dahmani,Patrick Caron,David Simonyan,Louis Lacombe,Armen Aprikian,Fred Saad,Michel Carmel,Simone Chevalier,Eric Lévesque,Chantal Guillemette
PURPOSE The contribution of 11-oxygenated androgens to the progression of lethal prostate cancer (PCa) remains unresolved. We hypothesized that evaluating circulating levels of 11-oxygenated androgens, such as the androgen receptor agonist 11-ketotestosterone (11KT), could serve as a potential predictor of the onset of castration-resistant PCa (CRPC). METHODS We used mass spectrometry to quantify 11-oxygenated
-
Cuff Conundrums: Best Practice Recommendations for Urethral Instrumentation With an Artificial Urinary Sphincter in Place. J. Urol. (IF 5.9) Pub Date : 2024-11-13 Samuel J Ivan,Joshua A Cohn,Jeffrey C Loh-Doyle,Aaron C Lentz,Jay Simhan
-
Clinical and Demographic Factors Linked to Low-Value Emergency Department Visits in Pediatric Patients With Spina Bifida. J. Urol. (IF 5.9) Pub Date : 2024-11-12 Peter Y Cai,Erin R McNamara,Hatim Thaker,Carlos R Estrada,Hsin-Hsiao S Wang
PURPOSE Identifying factors associated with emergency visits that could be delivered at lower cost sites may help guide population health strategies for pediatric patients with spina bifida. MATERIALS AND METHODS Emergency department encounters (2016-2023) by patients with spina bifida (younger than 18 years) in the Pediatric Health Information System were identified. Absence of clinical and imaging
-
Letter: Health Vulnerabilities of Spina Bifida Patients: Transition From Adolescents to Adults. J. Urol. (IF 5.9) Pub Date : 2024-11-11 Liangping Zhang
-
PD52-08 Adherence to Intracavernosal Injection Relative to Prescriber Choices and Patient Income: Erratum. J. Urol. (IF 5.9) Pub Date : 2024-11-08
-
Use and Disuse of Catheterizable Channels as the Primary Method of Emptying the Neuropathic Bladder: A Single Institutional Cohort Study. J. Urol. (IF 5.9) Pub Date : 2024-11-04 Yifan Meng Griffin,Rosalia Misseri,Joshua D Roth,Benjamin M Whittam,Pankaj Dangle,Shelly King,Kirstan K Meldrum,Martin Kaefer,Mark P Cain,Richard C Rink,Konrad M Szymanski
PURPOSE We aimed to assess long-term use of continent catheterizable urinary channels (CCCs) and explore potential risk factors of disuse. MATERIALS AND METHODS People undergoing appendicovesicostomy and Monti procedures at our institution were retrospectively reviewed (1991-2023). The main outcome was CCC disuse (not intermittently catheterizing channels as the primary method of bladder emptying)
-
Preoperative Immersive Virtual Reality (iVR) Applied to Percutaneous Nephrolithotomy: A Prospective Randomized Clinical Study of Surgical Planning and Clinical Outcomes. J. Urol. (IF 5.9) Pub Date : 2024-10-31 Andrei D Cumpanas,Mariah C Hernandez,Amanda McCormac,Marissa Ericson,Jaylen Lee,Jaime Altamirano-Villarroel,Candices M Tran,Zachary E Tano,Sohrab N Ali,Bruce M Gao,Pengbo Jiang,Roshan M Patel,Jaime Landman,Ralph V Clayman
PURPOSE Percutaneous nephrolithotomy (PCNL) is the procedure of choice for the management of complex or large renal stones. A major challenge for the surgeon, however, is the need to assimilate the nearly 2000 static images from a CT scan into a functional mental image to enable surgical planning. Accordingly, we investigated the potential of immersive virtual reality (iVR) to enhance surgical planning
-
Radiating for Two: Quantifying Radiation Exposure to Pregnant Urologists During Percutaneous Nephrolithotomy. J. Urol. (IF 5.9) Pub Date : 2024-10-31 Sikai Song,Akin S Amasyali,Daniel Jhang,Toby Clark,Kai Wen Cheng,Kyu Park,Nicole Mack,Cliff De Guzman,Ruby Kuang,Matthew Buell,Rose Leu,Kanha Shete,Ala'a Farkouh,Elizabeth A Baldwin,Evan Seibly,Zhamshid Okhunov,D Duane Baldwin
PURPOSE Current occupational recommendations limit fetal radiation dose to 1 mSv. With increased gender diversity in urology, understanding radiation exposure during pregnancy is crucial. The purpose of this study was to determine surgeon uterine radiation dose during percutaneous nephrolithotomy (PCNL) and compare effectiveness of several radiation reduction strategies in a cadaver model. MATERIALS
-
Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Non-Muscle-Invasive Bladder Cancer. J. Urol. (IF 5.9) Pub Date : 2024-10-29 Eunice Villegas,Katherine Lajkosz,Shayan Din,Cynthia Kuk,Amy Chan,Jethro C C Kwong,Christian Vitug,Bruce Gao,Otto Hemminki,Dhiral Kot,Jimmy Misurka,Peter Black,Michael Jewett,Mark S Soloway,Morgan Roupret,Eva Compérat,Joan Sweet,Thomas Seisen,Neil E Fleshner,Jeffrey Wrana,Theodorus H van der Kwast,Girish S Kulkarni,Alexandre R Zlotta
PURPOSE Patients with Ta low-grade (LG) NMIBC rarely develop metastases or die of it. Long-term data are scant and length of follow-up poorly defined. MATERIALS AND METHODS This retrospective study included 521 patients diagnosed with primary TaLG NMIBC (n = 491) or papillary urothelial neoplasm of low malignant potential (n = 30) from 1989 to 2019 at an academic center. Patient data were acquired
-
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION). J. Urol. (IF 5.9) Pub Date : 2024-10-24 Sandip M Prasad,Dimitar Shishkov,Nikola Vladimirov Mihaylov,Alexandre Khuskivadze,Pencho Genov,Vasyl Terzi,Max Kates,William C Huang,Michael J Louie,Sunil Raju,Brent Burger,Andrew Meads,Mark Schoenberg
PURPOSE To evaluate the efficacy and safety of UGN-102 chemoablation for the primary treatment of patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS ENVISION is an ongoing, multinational, single-arm, Phase 3 study in patients with a biopsy-proven recurrence of untreated low-grade intermediate-risk nonmuscle-invasive bladder cancer. Patients
-
Reply: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J. Urol. (IF 5.9) Pub Date : 2024-10-23 David Staskin,Janet Owens-Grillo,Elizabeth Thomas,Eric Rovner
-
-
Comparative Analysis of Holmium Laser Enucleation of the Prostate (HoLEP) and Robotic-Assisted Simple Prostatectomy (RASP) in BPH Management: A Systematic Review and Meta-Analysis. J. Urol. (IF 5.9) Pub Date : 2024-10-18 Tarek Benzouak,Abdulmalik Addar,Michael A Prudencio-Brunello,Ammar Saed Aldien,Steve E Amougou,Ahmad AlShammari,Mohammed Ramadhan,Serge Carrier,Mélanie Aubé-Peterkin,Fadl Hamouche
PURPOSE As the prevalence of benign prostatic hyperplasia (BPH) increases, the demand for surgical interventions that optimize patient outcomes while minimizing complications grows. This systematic review compares the efficacy, efficiency, and safety of holmium laser enucleation of the prostate (HoLEP) with robotic-assisted simple prostatectomy (RASP), providing insights for evidence-based surgical
-
Clinical Factors Associated With Suspicious 18F-DCFPyL PSMA PET Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL. J. Urol. (IF 5.9) Pub Date : 2024-10-18 Eric V Li,Richard Bennett,Austin Ho,Clarissa Wong,Ashorne K Mahenthiran,Sai Kaushik Shankar Ramesh Kumar,Zequn Sun,Hatice Savas,Steven P Rowe,Edward M Schaeffer,Hiten D Patel,Ashley Ross
PURPOSE There are limited data on PSMA PET/CT for workup of recurrence after radical prostatectomy (RP) at low PSA values. We evaluated a PSMA PET/CT cohort of patients with post-RP, focusing on patients with PSA < 0.5 ng/mL. MATERIALS AND METHODS We identified a retrospective cohort who underwent piflufolastat F-18 PSMA PET/CT across an 11 hospital system from July 2021 to February 2023. Prostate-specific
-
From Error to Excellence: An Evolving Paradigm for Improving the Diagnostic Process. J. Urol. (IF 5.9) Pub Date : 2024-10-16 Karen E Johnson,David F Friedlander,Matthew E Nielsen
-
Can We Be Less Active in Prostate Cancer Surveillance? J. Urol. (IF 5.9) Pub Date : 2024-10-16 Miko Filon,Brock O'Neil
-
Letter: The Extraperitoneal Midline Approach: A Game Changer to Access the Retroperitoneum? J. Urol. (IF 5.9) Pub Date : 2024-10-16 Christian Daniel Fankhauser,Silvan Sigg,Nirmish Singla
-
Letter: Enhancing Patient-Centered Communication in Endourologic Research: A Call for Adoption of ASCO's Language of Respect Guidelines. J. Urol. (IF 5.9) Pub Date : 2024-10-16 Jonathan Alcantar,Brandon Piyevsky,Mohammed Shahait,Ryan W Dobbs
-
Artificial Urinary Sphincter Implants in Men: A National Health Care Data System-Based Study to Assess Reinterventions in France. J. Urol. (IF 5.9) Pub Date : 2024-10-14 Louis Lenfant,Yoann Taillé,Emmanuel Chartier-Kastler,Bertrand Lukacs,Thomas Seisen,Morgan Roupret,Aurélien Beaugerie,Eric Vicaut,Pierre C Mozer
PURPOSE Significant concerns remain regarding the long-term outcomes of AMS 800 artificial urinary sphincter (AUS) implants in men. The objective was to assess the long-term AUS reintervention (replacement or removal) rates after a first-ever AUS implantation. MATERIALS AND METHODS This population-based retrospective cohort study included all men age ≥ 18 years in France who underwent a first-ever
-
Furthering the Capacity of Urologists to Shape the Field of Dissemination and Implementation Science and Enhance Clinical Practice. J. Urol. (IF 5.9) Pub Date : 2024-10-14 Shellie D Ellis,Ted A Skolarus
-
Artificial Intelligence-Based Assessment of Preoperative Body Composition is Associated With Early Complications After Radical Cystectomy. J. Urol. (IF 5.9) Pub Date : 2024-10-11 Vidit Sharma,Anthony Fadel,Matthew K Tollefson,Sarah P Psutka,Daniel J Blezek,Igor Frank,Prabin Thapa,Robert Tarrell,Lyndsay D Viers,Aaron M Potretzke,Robert P Hartman,Stephen A Boorjian,Boyd R Viers
PURPOSE We aimed to use a validated artificial intelligence (AI) algorithm to extract muscle and adipose areas from CT images before radical cystectomy (RCx) and then correlate these measures with 90-day post-RCx complications. MATERIALS AND METHODS A tertiary referral center's cystectomy registry was queried for patients who underwent RCx between 2009 and 2017 for bladder cancer. Eight hundred forty-three
-
Targeted Biopsy Is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer. J. Urol. (IF 5.9) Pub Date : 2024-10-09 Mary O Fakunle,Janet E Cowan,Samuel L Washington,Katsuto Shinohara,Hao G Nguyen,Peter R Carroll
PURPOSE Serial biopsy is a mainstay for patients on active surveillance (AS) for prostate cancer. multiparametric MRI targeting has become a standard. It is unclear whether targeted biopsy alone reliably identifies the dominant lesion, thereby obviating the need for systematic sampling. MATERIALS AND METHODS Participants enrolled in AS with early-stage prostate cancer (PSA <20, cT1-2, GG1-2) and underwent
-
Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J. Urol. (IF 5.9) Pub Date : 2024-10-09 Yair Lotan,Viswesh Krishna,Waleed M Abuzeid,Bryn Launer,Sam S Chang,Vrishab Krishna,Siddhant Shingi,Jennifer B Gordetsky,Thomas Gerald,Solomon Woldu,Eugene Shkolyar,Dickon Hayne,Andrew Redfern,Lisa Spalding,Courtney Stewart,Eduardo Eyzaguirre,Shamsunnahar Imtiaz,Vikram M Narayan,Vignesh T Packiam,Michael A O'Donnell,Roger Li,Loic Baekelandt,Steven Joniau,Tahlita Zuiverloon,Mario I Fernandez,Marcela
PURPOSE There are few markers to identify those likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG). We developed and validated artificial intelligence-based histologic assays that extract interpretable features from transurethral resection of bladder tumor digitized pathology images to predict risk of recurrence, progression, development of BCG-unresponsive
-
MP75-10 Nocturia Across the Heart Failure Continuum: Results From an Outpatient Urology Population: Erratum. J. Urol. (IF 5.9) Pub Date : 2024-10-09
-
-
Higher Morbidity and Mortality in Females With Fournier Gangrene Compared With Males: Insights From National Inpatient Sample Data. J. Urol. (IF 5.9) Pub Date : 2024-10-02 Behzad Abbasi,Emily Hacker,Umar Ghaffar,Nizar Hakam,Kevin D Li,Sultan Alazzawi,Adrian Fernandez,Hiren V Patel,Benjamin N Breyer
PURPOSE We compare Fournier gangrene in female and male patients and identify mortality-associated characteristics in both. MATERIALS AND METHODS We used National Inpatient Sample data (2016-2020) to identify Fournier gangrene cases and extracted demographic, comorbidity, and procedural variables. Multivariable regression models were used to identify mortality risk factors for both cohorts. RESULTS
-
Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric MRI? J. Urol. (IF 5.9) Pub Date : 2024-10-02 Yasin Bhanji,Mufaddal K Mamawala,Sean A Fletcher,Patricia Landis,Hiten D Patel,Katarzyna J Macura,Christian P Pavlovich
PURPOSE Men diagnosed with prostate cancer (PCa) considering active surveillance (AS) are recommended confirmatory biopsy (CBx). Whether this is necessary in the era of MRI-informed biopsies is questionable. MATERIALS AND METHODS We studied men with Grade Group (GG) 1 PCa at diagnostic biopsy (DBx) considering AS who underwent MRI and CBx (systematic + targeted) within 18 months. Outcomes were grade
-
An Automated Electronic Health Record Score to Estimate Length of Stay and Readmission in Patients Undergoing Radical Cystectomy for Bladder Cancer. J. Urol. (IF 5.9) Pub Date : 2024-10-02 Simon John Christoph Soerensen,Bogdana Schmidt,I-Chun Thomas,Maria E Montez-Rath,Alan E Thong,Kris Prado,Jay B Shah,Eila C Skinner,John T Leppert
PURPOSE Patients treated with radical cystectomy experience a high rate of postoperative complications and frequent hospital readmissions. We sought to explore the utility of the Care Assessment Need (CAN) score, derived from electronic health data, to estimate the risk of these adverse clinical outcomes, thereby aiding patient counseling and informed treatment decision-making. MATERIALS AND METHODS
-
Impact of Either Trendelenburg or Reverse Trendelenburg Positioning for Ureteroscopy Lithotripsy Procedures: A Systematic Review and Meta-Analysis. J. Urol. (IF 5.9) Pub Date : 2024-09-30 Henrique L Lepine,Fabio C Vicentini,Wilson R Molina,Carolina M Llata,Giovanni S Marchini,Fabio C M Torricelli,Carlos A Batagello,Alexandre Danilovic,William C Nahas,Eduardo Mazzucchi
PURPOSE Urologists encounter multiple challenges in managing ureteral stones with ureteroscopic laser lithotripsy. This meta-analysis assesses the effectiveness of alternative surgical positioning, reverse Trendelenburg (RevTren) and Trendelenburg (Tren), in reducing stone migration and enhancing outcomes compared with standard dorsal lithotomy positioning. MATERIALS AND METHODS A systematic review
-
Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer. J. Urol. (IF 5.9) Pub Date : 2024-09-30 Jose M Flores,Emily A Vertosick,Carolyn A Salter,Nicole Liso,Patrick Teloken,Boback Berookhim,Lawrence Jenkins,Sigrid Carlsson,Vincent Laudone,James Eastham,Andrew J Vickers,John P Mulhall
PURPOSE Testosterone (T) therapy (TTh) in men with T deficiency who have undergone radical prostatectomy (RP) for prostate cancer remains controversial. We aimed to assess the impact of TTh on biochemical recurrence (BCR) rates after RP in men with low-intermediate organ-confined disease. MATERIALS AND METHODS This study included men who underwent an RP at our institution for organ-confined prostate
-
Novel Intraprostatic MR-Guided Implantation of Multidrug-Eluting Microdevice for Testing of Systemic Therapy Agents In Situ: Proof of Concept in Intermediate-Risk and High-Risk Prostate Cancer. J. Urol. (IF 5.9) Pub Date : 2024-09-30 Benjamin V Stone,Christine A Dominas,Sharath K Bhagavatula,Sebastian W Ahn,Zuzana Tatarova,Juraj Jakubik,Destiny Matthew,Matthew Mossanen,Daniella Furtado,Kemal Tuncali,Nobuhiko Hata,Clare Tempany,Oliver Jonas,Adam S Kibel
PURPOSE The purpose of this study was to assess safety and feasibility of percutaneous MR-guided placement of an implantable microdevice (IMD) to evaluate in situ intratumor response to multiple pharmacologic agents in men with intermediate-risk and high-risk localized prostate cancer. MATERIALS AND METHODS Biocompatible IMDs measuring 750 µm in diameter and 5 mm in length were prepared with 20 reservoirs
-
Incidence of Erectile Dysfunction and Testosterone Deficiency in Testicular Cancer Survivors. J. Urol. (IF 5.9) Pub Date : 2024-09-30 Kshitij Pandit,Paul Riviere,Kylie Morgan,Tyler Nelson,Margaret Meagher,Dhruv Puri,Nuphat Yodkhunnatham,Leah Deshler,Elizabeth Duran,Daniel Sabater-Minarim,Juan Javier-Desloges,Amir Salmasi,Rana R McKay,Frederick Millard,Tung-Chin Hsieh,Darshan P Patel,Brent S Rose,Aditya Bagrodia
PURPOSE The aim of this project was to characterize the incidence of men's health disorders, specifically focusing on the incidence of erectile dysfunction (ED) and testosterone deficiency (TD) in a large, nationwide study of testicular cancer (TC) survivors treated in a centralized health care system. MATERIALS AND METHODS We conducted a retrospective cohort study of US veterans diagnosed with TC
-
A Patient-Prioritized Research Agenda for Clinical Trials in Kidney Stone Disease. J. Urol. (IF 5.9) Pub Date : 2024-09-20 Jonathan S Ellison,Kathryn E Flynn,Katherine Sheridan,Samantha Siodlarz,Jodi Antonelli,Christopher E Bayne,Hunter Beck,Christina Ching,Pankaj P Dangle,Casey Dauw,Carley Davis,Kim Hollander,Dirk Lange,Kristi Ouimet,Carswell Ouimet,Amy Y Pan,Kristina Penniston,Charles D Scales,Nayan Shah,Ryan Spiardi,Necole Streeper,Kristin Whitmore,Mike Witt,Liyun Zhang,Gregory E Tasian
PURPOSE To ensure that research on kidney stones provides meaningful impact for the kidney stone community, patients and caregivers should be engaged as stakeholders in clinical trial design, starting at study inception. This project aimed to elicit, refine, and prioritize research ideas from kidney stone stakeholders to develop a patient-centered research agenda for clinical trials. MATERIALS AND
-
Reevaluating the Definition of "Clinically Significant" Prostate Cancer as Grade Groups 2-5: An Imperative for Improved Risk Stratification. J. Urol. (IF 5.9) Pub Date : 2024-09-17 Sigrid V Carlsson,Peter R Carroll,Freddie C Hamdy
-
Letter: miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study. J. Urol. (IF 5.9) Pub Date : 2024-09-17 Klaus-Peter Dieckmann,Gazanfer Belge
-
Technical Considerations to Minimize False-Positive Findings in Blue Light Cystoscopy for Nonmuscle-Invasive Bladder Cancer. J. Urol. (IF 5.9) Pub Date : 2024-09-16 Alireza Ghoreifi,Siamak Daneshmand
-
Eleven-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors. J. Urol. (IF 5.9) Pub Date : 2024-09-13 Muhannad Alsyouf,Alireza Ghoreifi,Arman Ashrafi,Seyedeh-Sanam Ladi-Seyedian,Hamed Ahmadi,Madeleine Burg,Antoin Douglawi,Qi Nie,Ming Li,Sumeet Bhanvadia,Anne Schuckman,Hooman Djaladat,Siamak Daneshmand
PURPOSE A midline extraperitoneal approach for retroperitoneal lymph node dissection (EP-RPLND) has been associated with decreased morbidity compared to the transperitoneal approach. We aimed to review our 11-year experience in patients with germ cell tumors (GCTs) who underwent EP-RPLND at a single institution. MATERIALS AND METHODS All patients with GCT who underwent EP-RPLND between 2010 and 2021
-
Break Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial. J. Urol. (IF 5.9) Pub Date : 2024-09-10 Ben H Chew,Jonathan D Harper,Roger L Sur,Thomas Chi,Shubha De,Anne R Buckley,Ryan F Paterson,Victor K F Wong,Connor M Forbes,M Kennedy Hall,Ross Kessler,Seth K Bechis,Jason R Woo,Ralph C Wang,David B Bayne,Derek Bochinski,Trevor D Schuler,Tim A Wollin,Rahim Samji,Mathew D Sorensen
PURPOSE This study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones. MATERIALS AND METHODS Patients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days
-
Letter: Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma. J. Urol. (IF 5.9) Pub Date : 2024-09-10 Mattia Longoni,Giuseppe Rosiello,Alessandro Larcher,Francesco Montorsi,Umberto Capitanio
-
Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK. J. Urol. (IF 5.9) Pub Date : 2024-09-03 Neal D Shore,Ugo De Giorgi,Stephen J Freedland